Extension of the RealQuant® Lung Fusion Genes kit validation to cytological specimens
Project objectivesThe OSLO study is a multicenter study, which involves the evaluation of the performance of a CE-IVD diagnostic device for the purpose of extending the validation to NSCLC cytological samples. The in vitro diagnostic device in question detects and quantifies with the NanoString platform the transcripts of the rearrangements involving the ALK, ROS1 and RET genes in NSCLC. The device was designed, developed and validated by Diatech Pharmacogenetics. |
Start and end date |
| 10 October 2017 - 31 October 2018 |
Project Manager |
| Prof. Giuseppe Perrone |
Coordinating institution of the project |
| Università Campus Bio-Medico di Roma |
Other Institutions involved |
|
